Determination of the efficiency of 8 mg doxazosin XL treatment in patients with an inadequate response to 4 mg doxazosin XL treatment for benign prostatic hyperplasia.

Abstract

OBJECTIVE:

To compare the efficacy of 4 mg and 8 mg doxazosin XL treatments in patients with benign prostatic hyperplasia-related lower urinary tract symptoms and determine the efficiency of 8 mg in those patients with inadequate response to 4 mg.

METHODS:

A total of 162 patients were included in this study. Of the patients, 108 were randomized to receive 4 mg doxazosin XL (group 1), and 54 were randomized to receive 8 mg (group 2) treatments. After 1 month of treatment, 31 patients in group 1 whose quality of life (QoL) score was unchanged or had deteriorated were switched to 8 mg doxazosin XL treatment (group 1b).

RESULTS:

The mean age was 59.8 years. After 1 month of treatment, the mean alteration in the International Prostate Symptom Score was 3.9 and 5.2 (P = .028), for the maximum urinary flow rate (Q(max)), it was 3.0 and 3.6 mL/s (P = .206), and for the QoL score it was 1.3 and 1.7 (P = .038) in groups 1 and 2, respectively. For group 1b, during the period in which the patients were receiving 4 and 8 mg doxazosin XL treatments; the International Prostate Symptom Score changes were 1.3 and 3.6 (P <.001), the Q(max) changes were 1.6 and 3.2 mL/s (P <.019), and the QoL changes were 0.4 and 1.8 (P <.001) in groups 1 and 2, respectively.

CONCLUSION:

With no changes in side effects, 8 mg doxazosin XL treatment is an efficient choice for patients who did not have an adequate response to 4 mg doxazosin XL treatment.

• Authors: Tanju Keten, Yilmaz Aslan, Melih Balci, Altug Tuncel, Ovunc Bilgin, Cem Dilmen, Umit Ozdemir, Sedat Yahsi, Ozer Guzel, Ali Atan
• Journal: Urology (Urology) Vol. 85 Issue 1 Pg. 189-94 (Jan 2015) ISSN: 1527-9995 [Electronic] United States
• PMID: 25530384 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
• Copyright: Copyright © 2015 Elsevier Inc. All rights reserved.

Chemical References

• Adrenergic alpha-1 Receptor Antagonists
• Doxazosin

Topics

• Adrenergic alpha-1 Receptor Antagonists (administration & dosage)
• Aged
• Aged, 80 and over
• Doxazosin (administration & dosage)
• Humans
• Male
• Middle Aged
• Prostatic Hyperplasia (drug therapy)
• Quality of Life
• Treatment Failure